Beyzanur Ozogul, Unal Akar, Rabia Mercimek, Farzad Rokhsar Talabazar, Seyedali Seyedmirzaei Sarraf, Araz Sheibani Aghdam, Ali Ansari Hamedani, Luis Guillermo Villanueva, Dmitry Grishenkov, Ehsan Amani, Tugrul Elverdi, Morteza Ghorbani, Ali Koşar
{"title":"Hydrodynamic Cavitation-Induced Thrombolysis on a Clot-on-a-Chip Platform","authors":"Beyzanur Ozogul, Unal Akar, Rabia Mercimek, Farzad Rokhsar Talabazar, Seyedali Seyedmirzaei Sarraf, Araz Sheibani Aghdam, Ali Ansari Hamedani, Luis Guillermo Villanueva, Dmitry Grishenkov, Ehsan Amani, Tugrul Elverdi, Morteza Ghorbani, Ali Koşar","doi":"10.1002/anbr.202400112","DOIUrl":null,"url":null,"abstract":"<p>\nComplications from thrombosis constitute a massive global burden for human health. Current treatment methods have limitations and can cause serious adverse effects. Hydrodynamic cavitation (HC) is a physical phenomenon where bubbles develop and collapse rapidly within a moving liquid due to sudden pressure changes. These collapsing bubbles provide high targeted energy which can be used in a controlled environment with the help of microfluidic devices. This study introduces a new clot-on-a-chip (CoC) platform based on HC, evaluated for thrombolysis efficacy. The microfluidic device, paired with a polydimethylsiloxane (PDMS) microchip, generates cavitation bubbles at low upstream pressures (≤482 kPa), enabling microscale blood clot erosion. Different HC exposure conditions (varying pressure and duration) are assessed by changes in clot mass, diameter, and scanning electron microscopy (SEM). The largest mass reduction occurs at 482 kPa for 120 s, with a decrease of 6.1 ± 0.12 mg, while the most erosion in diameter of blood clots is obtained 482 kPa for 120 s with complete removal. SEM results show increasing damage to clot structure from less to more intense HC exposures. The CoC platform, at controlled pressures and durations, efficiently disrupts clot structure and offers a promising drug-free alternative for thrombolysis treatment.</p>","PeriodicalId":29975,"journal":{"name":"Advanced Nanobiomed Research","volume":"5 1","pages":""},"PeriodicalIF":4.0000,"publicationDate":"2024-10-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/anbr.202400112","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Advanced Nanobiomed Research","FirstCategoryId":"1085","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/anbr.202400112","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"ENGINEERING, BIOMEDICAL","Score":null,"Total":0}
引用次数: 0
Abstract
Complications from thrombosis constitute a massive global burden for human health. Current treatment methods have limitations and can cause serious adverse effects. Hydrodynamic cavitation (HC) is a physical phenomenon where bubbles develop and collapse rapidly within a moving liquid due to sudden pressure changes. These collapsing bubbles provide high targeted energy which can be used in a controlled environment with the help of microfluidic devices. This study introduces a new clot-on-a-chip (CoC) platform based on HC, evaluated for thrombolysis efficacy. The microfluidic device, paired with a polydimethylsiloxane (PDMS) microchip, generates cavitation bubbles at low upstream pressures (≤482 kPa), enabling microscale blood clot erosion. Different HC exposure conditions (varying pressure and duration) are assessed by changes in clot mass, diameter, and scanning electron microscopy (SEM). The largest mass reduction occurs at 482 kPa for 120 s, with a decrease of 6.1 ± 0.12 mg, while the most erosion in diameter of blood clots is obtained 482 kPa for 120 s with complete removal. SEM results show increasing damage to clot structure from less to more intense HC exposures. The CoC platform, at controlled pressures and durations, efficiently disrupts clot structure and offers a promising drug-free alternative for thrombolysis treatment.
期刊介绍:
Advanced NanoBiomed Research will provide an Open Access home for cutting-edge nanomedicine, bioengineering and biomaterials research aimed at improving human health. The journal will capture a broad spectrum of research from increasingly multi- and interdisciplinary fields of the traditional areas of biomedicine, bioengineering and health-related materials science as well as precision and personalized medicine, drug delivery, and artificial intelligence-driven health science.
The scope of Advanced NanoBiomed Research will cover the following key subject areas:
▪ Nanomedicine and nanotechnology, with applications in drug and gene delivery, diagnostics, theranostics, photothermal and photodynamic therapy and multimodal imaging.
▪ Biomaterials, including hydrogels, 2D materials, biopolymers, composites, biodegradable materials, biohybrids and biomimetics (such as artificial cells, exosomes and extracellular vesicles), as well as all organic and inorganic materials for biomedical applications.
▪ Biointerfaces, such as anti-microbial surfaces and coatings, as well as interfaces for cellular engineering, immunoengineering and 3D cell culture.
▪ Biofabrication including (bio)inks and technologies, towards generation of functional tissues and organs.
▪ Tissue engineering and regenerative medicine, including scaffolds and scaffold-free approaches, for bone, ligament, muscle, skin, neural, cardiac tissue engineering and tissue vascularization.
▪ Devices for healthcare applications, disease modelling and treatment, such as diagnostics, lab-on-a-chip, organs-on-a-chip, bioMEMS, bioelectronics, wearables, actuators, soft robotics, and intelligent drug delivery systems.
with a strong focus on applications of these fields, from bench-to-bedside, for treatment of all diseases and disorders, such as infectious, autoimmune, cardiovascular and metabolic diseases, neurological disorders and cancer; including pharmacology and toxicology studies.